Christoph Ullmer
Basel, BS 4058, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 54 publications
Correction to: ANG2 Blockade Diminishes Proangiogenic Cerebrovascular Defects Associated With Models of Hereditary Hemorrhagic Telangiectasia.
Journal: Arteriosclerosis, thrombosis, and vascular biology
Published: October 22, 2025
Identification of a translatable animal model for dry eye disease using comparative analysis of tear proteins across species.
Journal: The ocular surface
Published: February 03, 2025
Optimization of a DNA encoded library derived autotaxin inhibitor hit to a potent in vivo LPA lowering quinazolinone compound with a non‑zinc binding mode.
Journal: Bioorganic & medicinal chemistry letters
Published: December 11, 2024
Inhibition of Cathepsin S in Autoimmune CD25KO Mouse Improves Sjögren Disease-Like Lacrimal Gland Pathology.
Journal: Investigative ophthalmology & visual science
Published: July 17, 2024
A highly potent, orally bioavailable pyrazole-derived cannabinoid CB2 receptor-selective full agonist for in vivo studies.
Journal: bioRxiv : the preprint server for biology
Published: June 21, 2024
A Highly Potent, Orally Bioavailable Pyrazole-Derived Cannabinoid CB2 Receptor- Selective Full Agonist for In Vivo Studies.
Journal: ACS pharmacology & translational science
Published: May 07, 2024
RG7774 (Vicasinabin), an orally bioavailable cannabinoid receptor 2 (CB2R) agonist, decreases retinal vascular permeability, leukocyte adhesion, and ocular inflammation in animal models.
Journal: Frontiers in pharmacology
Published: May 01, 2024
Investigations into mRNA Lipid Nanoparticles Shelf-Life Stability under Nonfrozen Conditions.
Journal: Molecular pharmaceutics
Published: November 17, 2023
Effects of Cathepsin S Inhibition in the Age-Related Dry Eye Phenotype.
Journal: Investigative ophthalmology & visual science
Published: August 04, 2023
Last Updated: 09/26/2026